摘要
目的探讨2~3期慢性肾脏病患者应用和缓养肾方治疗的效果及其对肾功能、肾小管功能的影响。方法选取2021年6月至2023年6月常州市武进中医医院88例2~3期慢性肾脏病患者为研究对象,将其按照电脑随机数字表分成两组。对照组44例给予常规治疗,观察组44例增加和缓养肾方治疗。治疗3个月后,对比两组患者临床疗效、肾功能、肾小管功能、不良反应。结果两组临床疗效比较(Z=3.112,P=0.002<0.05);且观察组总有效率95.45%高于对照组81.82%(χ^(2)=4.062,P=0.044<0.05)。治疗后,观察组胱抑素-C(CysC)水平(0.95±0.17)mg/L、血尿素氮(BUN)水平(5.42±0.98)mmol/L、血肌酐(Scr)水平(98.23±11.70)μmol/L,均低于对照组(1.23±0.28)mg/L、(7.31±1.39)mmol/L、(121.16±17.92)μmol/L(P<0.001)。治疗后,观察组N-乙酰β-D氨基葡萄糖苷酶(NAG)水平(16.72±3.58)U/L、α1-微球蛋白(α1-MG)水平(3.08±0.75)mg/L、β2-微球蛋白(β2-MG)水平(0.30±0.06)mg/L,均低于对照组(20.81±4.02)U/L、(4.12±0.96)mg/L、(0.36±0.08)mg/L(P<0.001)。两组治疗期间均未出现明显不良反应。结论和缓养肾方联合常规治疗能够有效改善2~3期慢性肾脏病患者肾功能及肾小管功能,提高治疗效果,且安全性高。
Objective To investigate the therapeutic efficacy of Hehuan Yangshen Prescription on stage 2-3 chronic kidney disease(CKD)and the influence on renal function and tubular function.Methods Eighty-eight patients with stage 2-3 CKD in Wujin Hospital of Traditional Chinese Medicine from June 2021 to June 2023 were selected as the study objects.They were randomly assigned into the control group and observation group according to a computer random number table,with 44 patients per group.Conventional treatment was performed in both groups,and Hehuan Yangshen Prescription was additionally given to those in the observation group.After 3 months of treatment,the clinical efficacy,renal function,renal tubular function and adverse events were compared between the two groups.Results There was a significant difference in the clinical efficacy between the two groups(Z=3.112,P=0.002<0.05).The total effective rate was significantly higher in the observation group than that of control group(95.45%VS 81.82%,χ^(2)=4.062,P=0.044<0.05).After treatment,cystatin C(CysC,[0.95±0.17]mg/L VS[1.23±0.28]mg/L),blood urea nitrogen(BUN,[5.42±0.98]mmol/L VS[7.31±1.39]mmol/L)and serum creatinine(Scr,[98.23±11.70]μmol/L VS[121.16±17.92]μmol/L)were significantly lower in the observation group than those of control group(P<0.001).After treatment,n-acetyl beta D amino glycosidase enzymes(NAG,[16.72±3.58]U/L VS[20.81±4.02]U/L),alpha 1-microglobulin(α1-MG,[3.08±0.75]mg/L VS[4.12±0.96]mg/L)and beta 2-microglobulin(β2-MG,[0.30±0.06]mg/L VS[0.36±0.08]mg/L)were significantly lower in the observation group than those of control group(P<0.001).There were no obvious adverse events during treatment in both groups.Conclusion Hehuan Yangshen Prescription combined with conventional treatment can effectively improve renal function and renal tubular function in patients with stage 2-3 CKD,and improve the therapeutic effect with a high safety.
作者
蒋丽君
薛红良
冯青
张亚琦
孙正伟
JIANG Li-jun;XUE Hong-liang;FENG Qing;ZHANG Ya-qi;SUN Zheng-wei
出处
《中国疗养医学》
2024年第7期42-45,共4页
Chinese Journal of Convalescent Medicine
基金
常州市武进区科技项目(WS202108)。
关键词
和缓养肾方
慢性肾脏病
肾功能
肾小管功能
Hehuan Yangshen Prescription
Chronic kidney disease
Kidney function
Renal tubule function
